Weekly Digest – April 2026 Weekly Digest – April 2026 01 April 2026: RemeGen’s dual-antibody ADC RC288 for the treatment of advanced malignant solid tumors has been officially approved for clinical trials RemeGen’s dual-target ADC, RC288, has received clinical trial […]
Weekly Digest – April 2026 Weekly Digest – April 2026 30 March 2026: Aktis Oncology announces FDA clearance of Investigational New Drug applications for AKY-2519 Aktis Oncology’s radiopharmaceutical candidate AKY-2519 has received IND clearance from the U.S. FDA, enabling the […]
Weekly Digest – April 2026 Weekly Digest – April 2026 01 April 2026: Zai Lab announces global clinical trial collaboration and supply agreement to evaluate novel DLL3 ADC, Zocilurtatug Pelitecan, in combination with a bispecific T-cell Engager therapy Zai Lab […]
Weekly Digest – April 2026 Weekly Digest – April 2026 31 March 2026: NJ Bio and Ajinomoto Bio-Pharma Services partner to advance ADC and AOC development NJ Bio and Ajinomoto Bio-Pharma Services have entered into a research collaboration to expand […]
Weekly Digest – March 2026 Weekly Digest – March 2026 23 March 2026: Chugai obtains regulatory approval for Lunsumio and Polivy combination therapy for additional indication of relapsed or refractory large b-cell lymphoma Chugai has received approval in Japan (MHLW) […]
Weekly Digest – March 2026 Weekly Digest – March 2026 23 March 2026: ENHERTU now available in Japan as first ADC for the second-line treatment of patients with HER2 positive metastatic gastric cancer Japan’s PMDA has approved a label update […]
Weekly Digest – March 2026 Weekly Digest – March 2026 23 March 2026: ENHERTU approved in Japan as first tumor agnostic HER2 directed medicine for previously treated patients with HER2 positive metastatic solid tumors Japan’s MHLW has approved ENHERTU for […]
Weekly Digest – March 2026 Weekly Digest – March 2026 23 March 2026: GSK’s B7-H3-targeted ADC, Risvutatug rezetecan, granted Orphan Drug Designation for small-cell lung cancer in Japan GSK’s investigational B7-H3-targeted ADC, risvutatug rezetecan (Ris-Rez), has received ODD in Japan […]
Weekly Digest – March 2026 Weekly Digest – March 2026 25 March 2026: Tempus announces strategic collaboration with Daiichi Sankyo to advance AI-driven biomarker discovery and clinical differentiation across an ADC clinical program Tempus has entered into a strategic collaboration […]
Weekly Digest – March 2026 Weekly Digest – March 2026 23 March 2026: GlycoNex Inc. and Nippon Kayaku Co., Ltd. enter collaboration to advance next-generation ADC candidate GNX201-ADC GlycoNex and Nippon Kayaku have entered into a strategic collaboration to advance […]
